CKD Management: Can Quality Improvement Strategies Make a Difference?
"A meta-analysis reveals the effectiveness of quality improvement interventions in managing Chronic Kidney Disease (CKD) and improving patient outcomes."
Chronic Kidney Disease (CKD) affects approximately 10% of adults in North America, requiring multifaceted care to manage disease progression and complications. This includes addressing hypertension, proteinuria, cardiovascular health, and bone health. Despite clinical practice guidelines, many CKD patients do not receive optimal care, highlighting a significant gap in treatment efficacy.
Quality improvement (QI) interventions aim to continually strengthen healthcare system performance and can help bridge these care gaps within the CKD population. By targeting various aspects of healthcare delivery—from the system itself to individual providers and patients—QI strategies have proven successful in managing other chronic conditions. For instance, in diabetes mellitus, QI strategies have been linked to notable reductions in glycated hemoglobin (HbA1c), blood pressure, and LDL cholesterol levels.
While the potential of QI interventions in CKD management is recognized, it remains unclear which specific strategies are most effective. To address this knowledge gap, a systematic review and meta-analysis was conducted to synthesize available literature on QI strategies for CKD patients and to describe their impact on clinical outcomes.
CKD Burden and Consequences
Chronic kidney disease can lead to high blood pressure, heart disease, stroke, and early death. The NIDDK reports that CKD is slightly more common in women (14%) than men (12%), affects about 20% of non-Hispanic Black adults, and affects approximately 12% of non-Hispanic White adults. More than 808,000 people in the United States are living with end-stage kidney disease, with 68% on dialysis and 32% having a kidney transplant.
From Renal Insufficiency to CKD
At the beginning of the new millennium, chronic kidney disease replaced the previously used label renal insufficiency. The modern definition describes CKD as an alteration in kidney morphology, function, blood, or urine composition lasting at least three months. This broad definition can include conditions associated with normal kidney function, such as kidney scarring after acute pyelonephritis or having a single kidney.
The Impact of Quality Improvement Strategies on CKD Care
The systematic review included 21 studies, comprising 15 patient-level randomized trials (3,298 patients) and six cluster-randomized trials (30,042 patients). These studies evaluated the effectiveness of various QI strategies on different clinical outcomes relevant to CKD management.
- Reduced Dialysis Incidence: Seven trials showed that QI strategies reduced the incidence of dialysis (RR, 0.85; 95% CI, 0.74 to 0.97), suggesting a significant impact on slowing disease progression.
- Improved LDL Cholesterol Concentrations: Four trials demonstrated that QI interventions lowered LDL cholesterol concentrations (mean difference, -17.6 mg/dL; 95% CI, -28.7 to -6.5), highlighting benefits for cardiovascular health.
- Increased Use of Renin-Angiotensin-Aldosterone System Inhibitors: Nine trials indicated that QI strategies increased the likelihood of patients receiving renin-angiotensin-aldosterone system inhibitors (RR, 1.16; 95% CI, 1.06 to 1.27), crucial for managing blood pressure and proteinuria.
Implementation Gaps in CKD Care
Recent reviews indicate that quality-improvement implementation is not consistently documented in chronic kidney disease research. One cited review found that fidelity was reported in fewer than half of randomized trials of quality-improvement initiatives designed to improve CKD management. Research on kidney-transplant care also notes that existing reviews have focused mainly on primary-care interventions for CKD, with limited attention to specialized populations such as transplant recipients.
Limits of the Evidence
Evidence for the effectiveness of quality-improvement strategies in CKD management remains limited. The reported estimates were constrained by the small number of studies available and by inconsistent adherence to quality-improvement principles. These limitations make it difficult to determine how reliably such strategies improve CKD care across settings.
Comparing Advanced CKD Pathways
Comparative research has examined dialysis and conservative kidney management in older adults with advanced CKD. The stated areas of comparison include survival, quality of life, hospitalization, and prognostic tools. Broader CKD management reviews describe the condition as progressive and complex, requiring an approach that addresses treatment and prevention of complications.
Looking Ahead: Optimizing CKD Care with QI Strategies
Quality improvement interventions show promise in enhancing specific aspects of CKD care, particularly in reducing dialysis incidence, improving LDL cholesterol levels, and increasing the use of essential medications. While the effectiveness estimates are currently limited by the number of studies and adherence to QI principles, these findings underscore the potential for QI strategies to materially improve patient outcomes and healthcare delivery in CKD management. Future research should focus on addressing existing gaps, refining QI methodologies, and ensuring fidelity to QI principles to maximize the impact on a broader range of clinical outcomes.
Turning Guidelines Into Care
CKD is a complex disease that can progress to renal dysfunction, end-stage kidney disease, and cardiovascular disease. Guideline-based strategies are available to prevent CKD progression and complications, but their implementation in clinical practice remains uncertain. The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD was published in March 2024 in Kidney International.
Precision and Global Action
CKD management is moving toward new tools and interventions for diagnosis and care. Recent perspectives identify new biomarkers, imaging methods, and artificial intelligence as developments relevant to improving the quality and precision of CKD care. CKD affects over 850 million people globally, making prevention of its development and progression an urgent priority.
Care in Real-World Contexts
A published clinical case described a 74-year-old man evaluated for CKD before a planned transcatheter aortic-valve replacement. CKD affects approximately 10% of adults worldwide and is associated with elevated cardiovascular risk, including heart failure, as well as comorbidities such as type 2 diabetes. In low- and middle-income countries, the increasing burden of CKD is creating greater demand for expensive kidney replacement therapies and challenging health systems.